Mobile Cardiac Telemetry Diagnostic Yield Much Higher than Event or Holter

With the Centers for Disease Control and Prevention (CDC) citing 610,000 American deaths per year from heart disease and 735,000 heart attack victims, it is extremely important to implement the best preventative and diagnostic measures possible. ReactDx, creators of state-of-the-art telemetry unit, the TelePatch™ MCT, is sharing a new report that suggests Mobile Cardiac Telemetry (MCT) provides better results than Holter and Event monitoring.

Jean-Patrick Tsang and Shunmugam Mohan conducted research that was published in the US National Library of Medicine National Institutes of Health to determine if patients treated in a hospital setting fared better in three specific areas when using MCT versus Holter and Event monitors. They examined the diagnosis of arrhythmia, the therapeutic management of arrhythmia drugs, and the overall costs of care. All of the information obtained for this analysis came from the Truven database.

After reviewing the findings, Tsang and Mohan concluded that both hospitals and their patients would benefit from using MCT over Holter and Event monitors. Not only was the diagnostic yield 40 percent higher with MCT versus Holter and Event monitors, but the MCT wearers also had a 20 percent higher rate of having drug therapy initiated after the diagnostic findings came in.

When it comes to per-patient cost, Mobile Cardiac Telemetry resulted in savings in the five digits. This was found to be true for subjects that had the following procedures: ablation, coronary artery bypass graft, and valve septa.

The authors reviewed 57 months of collected data on a total of 231,000 patients. Of those subjects, 14,000 were given Mobile Cardiac Telemetry, 54,000 an Event monitor, and 163,000 a Holter monitor. For control purposes, all of the individuals were similar when it came to age, physical location, type of cardiovascular disease, and class of prescribed cardiovascular drugs.

There is a reason that heart disease is referred to as the “silent killer.” Being able to detect and treat arrhythmias in a timely manner is vital. ReactDx’s telemetry units are widely regarded as the most technologically advanced in the industry. Contact ReactDx at 800-234-3278 to learn more, or visit our News & Updates page for that latest info.

Jodi is a seasoned Human Resources professional who thrives on change and transformation. She fell in love with Human Resources when she attended Penn State University for graduate school in Public Administration with a curriculum that emphasized Human Resources. After earning her Master’s degree she began her career in the manufacturing industry in Talent Acquisition and was eventually assigned the overall HR Management responsibility of three divisions which included collective bargaining. Ultimately, she made her way to transitioning a new division of a Fortune 100 company under the corporate model as well as developing and executing Human Resources policies and procedures across a broad range of functional disciplines. At the next juncture of her career, she was tapped on the shoulder by former Executives that she previously worked with to join in on an exciting start-up. Today, Jodi is the Vice President of Talent Relations and Development for Medicomp Inc dba ReactDx and is responsible for managing the strategic Human Resources function which includes mergers and acquisitions for this rapidly expanding company.

Jodi and her husband enjoy landscaping, finding new restaurants and traveling whenever life gives them the opportunity.

    *This form is intended for sales inquiries/information only. Do not include any patient health information (PHI) with your submission.

    On: all lights. Off: no light. Monitoring - Good: green light. Symptom press: green light, sound. Check Pendant: blue light. Check Battery: red light, sound.
    Do: wear always, fully insert in cradle, turn off to charge, dry, key near handset, return promptly. Don't: discard pendant, submerge, move patch